Peculiarity of recovery of the hypothalamic–pituitary–gonadal (HPG) axis, in men after using androgenic anabolic steroids

  • Authors: Lykhonosov M.P.1, Babenko A.Y.2,3, Makarin V.A.4, Fedotov Y.N.4
  • Affiliations:
    1. Pavlov First Saint Petersburg State Medical University
    2. Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
    3. Almazov National Medical Research Centre, St. Petersburg, Russia
    4. University hospital of Saint-Petersburg State University, St. Petersburg, Russia
  • URL: https://probl-endojournals.ru/probl/article/view/12223
  • DOI: https://doi.org/10.14341/probl12223
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Abstract


Backgraund: There is insufficient data on the duration of recovery of HPG axis after abuse of androgenic anabolic steroids (AAS).

Aims: to evaluate the recovery of HPG axis in men, AAS users, after a 3-month of cessation of their use and after PCT.

Materials and methods: An observational, single-center, prospective, sampling, open, uncontrolled study was conducted among male AAS users. While using of AAS and 3 months after the refusal of their administration and PCT, the clinical symptoms of hypogonadism were evaluated, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone (Tt), prolactin, estradiol, inhibin B, thyroid-stimulating hormone (TSH) were determined. The scheme of rehabilitation therapy was the same and did not change throughout the study. Recovery criteria: Tt>3.4 ng/ml and LH>1.24 mIU/ml. The study was conducted from January to August 2019. Fisher's exact test, Mann-Whitney U-test, and Spearman's rank correlation coefficient were used. The differences were considered statistically significant at p <0.05.

Results: The study included 44 men, their age 29 years [27.75;34], the duration of the use of AAS is 6 months [3.52;7]. During the use of AAS: LH 0.2 mIU/ml [0.04;0.47], Tt - 4.34 ng/ml [1.05;8.81]. In this group, the number of men with a LH level<1.24mIU/ml was 84% (n=37) and Tt<3.4ng/ml was 47.7%(n=21). After 3 months, the LH level reached 4.12 mIU/ml [2.58;5.84], Tt - 4.55 ng/ml [3.76;6.24]. At the same time, the level of Tt<3.4 ng/ml remained in 20.5% (n=9); LH<1.24 mIU/ml in 4.5%(n=2) men. According to the level of recovery of LH and Tt, patients were divided into two groups: with satisfying (n=35;79.5%) and poor (n=9;20.5%) recovery. A clear correlation was established between the duration of use (-0.857; p<0.0001), the amount (-0.443; p=0.003), the dose (-0.7825; p<0.0001), the type of AAS (-0.698; p<0.0001).

Conclusions: A three-month refusal to use AAS with PCT led to the restoration of HPG axis a in 79.5% of the volunteers. The negative effect of the duration of use, the number of simultaneously administered drugs, their dose and type of AAS on the restoration of HPG axis was established. 


Full Text

About the authors

Mykola P. Lykhonosov

Pavlov First Saint Petersburg State
Medical University

Author for correspondence.
Email: likhonosov.np@gmail.com
ORCID iD: 0000-0001-6460-5226
SPIN-code: 2102-5358

Russian Federation, 6/8 L’va Tolstogo street, St. Petersburg, 197022 Russian Federation

MD, PhD student Pavlov First Saint Petersburg State
Medical University

Alina Y. Babenko

Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia;
Almazov National Medical Research Centre, St. Petersburg, Russia

Email: alina_babenko@mail.ru
ORCID iD: 0000-0002-0559-697X
SPIN-code: 9388-1077

Russian Federation, 6/8 L’va Tolstogo street, St. Petersburg, 197022 Russian Federation; 2 Akkuratova street, St. Petersburg 197341

MD, associate professor of the faculty of therapy with a course of endocrinology, cardiology and functional diagnostics named after G.F. Langa with the clinic of the First St. Petersburg State Medical University named after Acad. I.P.Pavlova Ministry of Health of Russia

Viktor A. Makarin

University hospital of Saint-Petersburg State University, St. Petersburg, Russia

Email: mvaviktor@mail.ru
ORCID iD: 0000-0003-1710-8045
SPIN-code: 8885-2085

Russian Federation, Universitetskaya nab., 7/9, St. Petersburg, 199034

MD, PhD, Head of the medical and diagnostic complex for Korablestroitelej University hospital of Saint-Petersburg State University

Yury  N. Fedotov

University hospital of Saint-Petersburg State University, St. Petersburg, Russia

Email: 6762525@gosmed.ru
ORCID iD: 0000-0003-0445-9428

Russian Federation, Universitetskaya nab., 7/9, St. Petersburg, 199034

MD, PhD, Professor, First Vice-Rector for Medical Activities, Director of the N. I. Pirogov Clinic for High Medical Technologies

References

  • Coward R, McBride Ja. Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use. Asian Journal of Andrology. Medknow; 2016;18(3):373. http://dx.doi.org/10.4103/1008-682x.173938.
  • Дедов И.И., Мельниченко Г.А., Роживанов Р.В., Курбатов Д.Г. Рекомендации по диагностике и лечению гипогонадизма (дефицита тестостерона) у мужчин. Проект // Проблемы Эндокринологии. - 2015. - Т. 61. - №5. - C. 60-71. [Dedov I.I., Mel'nichenko G.A., Rozhivanov R.V., Kurbatov D.G. The recommendations on diagnostics and treatment of male hypogonadism (deficit of testosterone). The project // Problems of Endocrinology. - 2015. - Т. 61. - №5. - C. 60-71. (In Russ.)] https://doi: 10.14341/probl201561560-71.
  • Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. The Endocrine Society; 2018 Mar 17;103(5):1715–44. http://dx.doi.org/10.1210/jc.2018-00229.
  • El Osta R. et al. Anabolic steroids abuse and male infertility //Basic and clinical andrology. – 2016. – Т. 26. – №. 1. – С. 2. doi: 10.1186 / s12610-016-0029-4.
  • Лихоносов НП, Бабенко АЮ. Медицинский аспект использования анаболических андрогенных стероидов у мужчин, посещающих тренажерные залы Санкт-Петербурга. Проблемы Эндокринологии. 2019;65(1):19-30. [Lykhonosov MP, Babenko AY. The medical aspect of using anabolic androgenic steroids in males attending gyms of Saint-Petersburg. Problems of Endocrinology. 2019;65(1):19-30. doi: 10.14341/probl9832. (In Russ.)].
  • Park HJ. Anabolic steroid-induced hypogonadism: a challenge for clinicians. Journal of Exercise Rehabilitation. Korean Society of Exercise Rehabilitation; 2018 Feb 26;14(1):2–3. http://dx.doi.org/10.12965/jer.1836036.018.
  • Xuan X-J, Zhu Z-G, Zhao Z-G, et al. Predictive significance of serum inhibin B on testicular haploid gamete retrieval outcomes in nonobstructive azoospermic men. Asian Journal of Andrology. Medknow; 2019;21(2):137. http://dx.doi.org/10.4103/aja.aja_94_18.
  • Tatem AJ, Beilan J, Kovac JR, Lipshultz LI. Management of Anabolic Steroid-Induced Infertility: Novel Strategies for Fertility Maintenance and Recovery. The World Journal of Men’s Health. Korean Society for Sexual Medicine and Andrology (KAMJE); 2019;37. http://dx.doi.org/10.5534/wjmh.190002.
  • Об утверждении стандарта первичной медико-санитарной помощи при гипогонадизме. Приказ Минздрава России от 09.11.2012 N 780н. Зарегистрирован в Минюсте России 22.01.2013 N 26656. [Ob utverzhdenii standarta pervichnoj mediko-sanitarnoj pomoshhi pri gipogonadizme. Prikaz Minzdrava Rossii ot 09.11.2012 N 780n. Zaregistrirovan v Minyuste Rossii 22.01.2013 N 26656. (In Russ)].
  • Bhasin S., Brito J.P., Cunningham G.R. et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1–30. http://dx.doi.org/10.1210/jc.2018-00229.
  • Bland M. (2000) An Introduction to Medical Statistics, 3rd. ed. Oxford University Press, Oxford. – 432 p. – P.335-347.
  • Collins R. The war on anabolic-androgenic steroids. Human Enhancement Drugs. Routledge; 2019 Jun 12;264–79. http://dx.doi.org/10.4324/9781315148328-19.
  • Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opinion on Pharmacotherapy. Informa Healthcare; 2014 Apr 23;15(9):1247–64. http://dx.doi.org/10.1517/14656566.2014.913022.
  • Christou MA, Tigas S. Recovery of reproductive function following androgen abuse. Current Opinion in Endocrinology & Diabetes and Obesity. Ovid Technologies (Wolters Kluwer Health); 2018 Jun;25(3):195–200. http://dx.doi.org/10.1097/med.0000000000000406.
  • Kumanov P, Nandipati K, Tomova A, Agarwal A. Inhibin B is a better marker of spermatogenesis than other hormones in the evaluation of male factor infertility. Fertility and Sterility. Elsevier BV; 2006 Aug;86(2):332–8. http://dx.doi.org/10.1016/j.fertnstert.2006.01.022.
  • Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Practice & Research Clinical Endocrinology & Metabolism. Elsevier BV; 2009 Dec;23(6):793–800. http://dx.doi.org/10.1016/j.beem.2009.08.003.

Statistics

Views

Abstract - 142

PDF (Russian) - 0

PlumX

Dimensions


Copyright (c) Lykhonosov M.P., Babenko A.Y., Makarin V.A., Fedotov Y.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies